Marshall Edwards, an oncology company, has hired industry veteran Thomas Zech as chief financial officer, less than two months after appointing Daniel Gold as chief executive officer (CEO).
Zech joins Marshall Edwards with more than 35 years of experience in finance and accounting, including over 20 years in the life science industry. He replaces departing CFO David Seaton, who also served as acting CEO from December 2009 until the appointment of Gold in April 2010.
Most recently, Zech served as vice president, finance and CFO at Pacira Pharmaceuticals, a specialty pharmaceutical company founded in 2007 through the acquisition of the former SkyePharma injectable business. He transitioned to Pacira Pharmaceuticals from SkyePharma, where he joined in 1999 as controller and corporate secretary. Previously he held senior finance positions at Stratagene, Advanced Tissue Sciences, Allied Holdings and Psicor. Zech earned his bachelor’s degree in accounting from Lawrence Technological University and his master’s degree in finance from the University of Detroit.
The annual BNP Paribas Cash Management University kicked off on Thursday morning with treasury professionals congregating in Paris from across Europe.
APIs may be a solution to MT940 challenges, says Karen Fagan, treasury operation manager, for British television company, ITV.
Kicking off the first day of the Singapore Fintech Festival, issues with cryptocurrencies were addressed by MIT media labs director, Joi Ito, and panels of technology leaders discussed how they’re using data analytics.
Sibos 2017 day two highlights: Brexit and banking, and why ‘data is the new oil’ in financial services
How nation first politics can impact global financial organisations It’s clear that data and regulation are the two key topics that are ... read more